Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Jakafi, Jakavi
Ruxolitinib, a Janus kinase (JAK) 1 and 2 inhibitor, is used to treat myelofibrosis, polycythemia vera, and graft-versus-host disease. It works by interfering with the JAK-STAT signaling pathway, which plays a crucial role in cell growth and inflammation, particularly in blood cell production. This helps to reduce symptoms such as enlarged spleen, anemia, and constitutional symptoms in myelofibrosis, control red blood cell production in polycythemia vera, and mitigate the immune response in graft-versus-host disease.
For treatment of myelofibrosis, polycythemia vera, and graft-versus-host disease.
Serious infections, including tuberculosis, invasive fungal infections, and bacterial, viral, and other opportunistic infections, can occur. Progressive multifocal leukoencephalopathy, including fatal cases, has been reported. Risk of herpes zoster infections. Increased risk of lymphoma and other malignancies, including skin cancers. Increased risk of nonmelanoma skin cancer in patients with myelofibrosis.
Outcome:
Increased ruxolitinib levels
Mechanism:
Inhibition of ruxolitinib metabolism
Outcome:
Increased risk of bleeding
Mechanism:
Additive effects on platelet function
Outcome:
Decreased ruxolitinib absorption
Mechanism:
Chelation
Most likely new formulation: Extended-release formulation (Year 2025, 80% confidence)
Based on current usage trends and clinical trial results, there is a 70% likelihood of expanded indications for ruxolitinib in other inflammatory conditions within the next 5 years.
Kinase Inhibitor, JAK Inhibitor
Pyrazole